Status:
COMPLETED
A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Diabetes Mellitus Type 2
Eligibility:
All Genders
30-75 years
Phase:
PHASE2
Brief Summary
This study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of GK Activator (2) in combination with metformin, compared to that of placebo (metformin monotherapy), in patients wi...
Eligibility Criteria
Inclusion
- adult patients 30-75 years of age;
- type 2 diabetes mellitus;
- individual maximal tolerated daily dose of metformin monotherapy for \>=3 months prior to screening.
Exclusion
- type 1 diabetes mellitus;
- any oral anti-hyperglycemic medication, other than metformin monotherapy, during last 3 months
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2007
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT00266253
Start Date
November 1 2005
End Date
March 1 2007
Last Update
November 2 2016
Active Locations (47)
Enter a location and click search to find clinical trials sorted by distance.
1
Phoenix, Arizona, United States, 85012
2
Chula Vista, California, United States, 91910
3
Los Angeles, California, United States, 90057
4
Kissimmee, Florida, United States, 34741